Fucoidan for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Fucoidan for Health & Longevity

Created on 07/19/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A sulfate-rich sugar from brown seaweed, eaten as food and sold as a supplement. The most consistent signals are on immune function and inflammation, with modest blood-pressure and cholesterol changes in small studies. Interest in cancer support and aging is early and mixed. Product species, molecular size, and purity strongly shape activity; generally well tolerated. (Full Review)

Protocol

Standard Dose
100–300 mg/day
Standardized brown-seaweed extract; 1–3 g/day reserved for supervised oncology settings
Timing
With food
Morning dosing common; timing not critical to efficacy
Dosing Frequency
Once daily
Gram-level doses split into 2–3 servings for tolerability
Time to effect
Immune & Vaccine Response
Several weeks
Immune and vaccine-response effects observed over several weeks of use
Blood Pressure & Lipids
~3 months
Blood-pressure and lipid changes seen in trials at roughly 3 months
Acute Effect
None
No immediate, perceptible acute effect

Benefits

Contraindications
  • Active bleeding disorders or unmonitored therapeutic anticoagulation
  • Within 1–2 weeks of scheduled surgery
  • Pregnancy or breastfeeding
  • Iodine-sensitive thyroid disease (high-iodine whole-seaweed products)
  • Known seaweed or shellfish allergy
    •
Key Interactions
  • Anticoagulants & antiplatelets (warfarin, DOACs, heparin, clopidogrel)
  • Aspirin & NSAIDs (ibuprofen, naproxen)
  • Blood-thinning supplements (fish oil, ginkgo, vitamin E, garlic, nattokinase)
  • Antihypertensive & antidiabetic drugs
  • Iodine-containing supplements (kelp, whole seaweed)
  • Blood-pressure-lowering supplements (garlic, coenzyme Q10, magnesium, potassium)
  • Immunosuppressant therapy
    •

Risk & Side Effects

  • High:
  • Medium: Bleeding risk & anticoagulant potentiation
    •
  • Low: Gastrointestinal discomfort; iodine excess & thyroid effects; heavy-metal contamination; additive blood-pressure lowering
    •
  • Speculative: Immune overstimulation; allergic reactions
    •

Monitoring

Marker Target Why
hs-CRP < 1.0 mg/L (optimal < 0.5) Tracks systemic inflammation
LDL-C < 100 mg/dL (optimal 70–100) Detects the modest lipid-lowering effect
Fasting glucose / HbA1c 75–90 mg/dL; HbA1c < 5.4% Monitors glycemic effects
TSH 0.5–2.0 mIU/L Detects iodine-driven thyroid dysregulation
INR 0.8–1.1 (if not anticoagulated) Detects additive blood-thinning effect and bleeding risk
Platelet count 150–400 ×10⁹/L Reference for bleeding-risk assessment

Cadence: Recheck relevant markers at ~8–12 weeks, then every 6–12 months; on anticoagulants, INR every 1–2 weeks after initiation until stable

Qualitative Assessment

  • Energy levels and general vitality
  • Frequency and severity of colds or infections
  • Digestive comfort (absence of bloating or loose stools)
  • Absence of unusual bruising or bleeding
  • Blood-pressure readings trending favorably where relevant
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.